Pure Global
NCT06125717

Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP

A Phase 1, Randomized, Rater and Subject Blinded Placebo Controlled Study to Evaluate the Safety, Reactogenicity, Tolerability and Immunogenicity of a Standard and a Fractional Dose of H1 Influenza Vaccine Delivered by VX-103 (a MIMIX Microneedle Patch (MAP) System) in Healthy Adults ≥18-39 Years of Age
Vaxess Technologies·Phase 1·ClinicalTrials.gov·biologicalCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Influenza
Drug/Device/Intervention
H1 influenza antigen
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Vaxess Technologies
Location
Toronto,Mirabel,Pointe-Claire, Canada
Timeline & enrollment
Phase
Phase 1
Start date
Jul 02, 2022
End date
Mar 13, 2023
Enrollment
45 participants
Primary outcome

To determine the safety of VX-103 delivered as a single MIMIX MAP immunization

Summary

A Phase 1, Randomized, Rater and Participant Blinded Placebo Controlled Study to Evaluate the
 Safety, Reactogenicity, Tolerability and Immunogenicity of a Standard and a Fractional Dose
 of H1 Influenza Vaccine Delivered by VX-103 (a MIMIX Microneedle Array Patch (MAP) System) in
 Healthy Adults ≥18-39 Years of Age

ICD-10 classifications
Influenza and pneumoniaInfluenza due to identified seasonal influenza virusInfluenza with other manifestations, seasonal influenza virus identifiedInfluenza with pneumonia, seasonal influenza virus identifiedInfluenza due to identified zoonotic or pandemic influenza virus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06125717
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06125717 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vaxess Technologies and is currently Completed. The study focuses on Influenza. Target enrollment is 45 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.